Seminars in Oncology
Volume 33, Supplement 10 , Pages S15-S18, October 2006

Bevacizumab in the Treatment of Metastatic Colorectal Cancer (mCRC) in Second- and Third-Line Settings

  • Bruce J. Giantonio

      Affiliations

    • Dr Giantonio serves on the Genentech BioOncology speakers bureau and is a paid consultant to Genentech and Sanofi-Aventis.
    • Corresponding Author InformationAddress reprint requests to Bruce J. Giantonio, MD, 12 Penn Tower, 3400 Spruce St, Philadelphia, PA 19104, USA.

Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0093-7754(06)00314-9

doi:10.1053/j.seminoncol.2006.08.003

Seminars in Oncology
Volume 33, Supplement 10 , Pages S15-S18, October 2006

Article Tools

* Image Usage & Resolution